Skip to main content
SP5007,677.28+0.32%DOW53,577.40+0.30%NASDAQ26,151.30+0.66%BTC$78,580.00-0.43%ETH$2,441.22-1.64%GOLD$4,715.90+0.46%OIL$81.11-1.52%
Smart Investors Daily
Sign InSign Up Free
YD

NASDAQ · YDESW

YD Bio Limited Warrants

Healthcare · Biotechnology

$0.36

Down-$0.00 (-1.18%)

Updated Aug 25, 2026, 9:58 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
3.98M
P/E ratio
-14.54
Dividend yield
0.00%
52-week range
$0.19 – $0.77
Volume
2.61K
Avg. volume
80.12K

Price performance

YDESW price history

1M range · 15 trading sessions · Daily adjusted prices

YDESW closed at $0.36 after 15 trading sessions, up 25.59% for the selected period.

Last close
$0.36
Period change
+25.59%
Period low
$0.22
Period high
$0.41
Daily close
View OHLC price history
YDESW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 24, 2026$0.2584$0.3642$0.2584$0.36422.61K
Aug 21, 2026$0.41$0.41$0.41$0.41507
Aug 19, 2026$0.355$0.40$0.34$0.3739.32K
Aug 18, 2026$0.27$0.37$0.255$0.340133.41K
Aug 17, 2026$0.2405$0.26$0.1913$0.2527.15K
Aug 13, 2026$0.2136$0.2699$0.1904$0.269973.21K
Aug 11, 2026$0.30$0.30$0.27$0.29522.49K
Aug 10, 2026$0.23$0.299$0.23$0.2993.33K
Aug 5, 2026$0.21$0.25$0.21$0.237.56K
Aug 3, 2026$0.2301$0.2301$0.2301$0.23018.01K
Jul 31, 2026$0.2301$0.25$0.2301$0.251.02K
Jul 30, 2026$0.25$0.25$0.25$0.251.11K
Jul 29, 2026$0.27$0.27$0.22$0.2218.73K
Jul 28, 2026$0.31$0.31$0.27$0.2829.02K
Jul 27, 2026$0.263$0.29$0.263$0.29406

Latest YDESW news

The latest Smart Investors Daily articles mentioning YDESW.

Stock researchCompany · Overview

YDESW research

Overview

Company profile and research snapshot.

Company profile

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 11, 2026

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

Two chrono-nutrition formulations — a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula — were developed in collaboration with the Taiwan CDHA and FHI. The Company intends to expand this approach by exploring additional opportunities for collaboration with other physicians and healthcare organizations. TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylati

Yahoo · Aug 4, 2026

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

Published in Bioengineering, a collaborative study with Taipei Medical University researchers identifies key molecular candidates to help guide the development of regenerative therapies for corneal disease. TAIPEI, Taiwan, Aug. 04, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today highlighted the publication of a new peer-reviewed study in th

Yahoo · Jan 29, 2026

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced it has entered into a binding Letter of Intent (the “LoI”) to acquire all shares, assets, and business of Safe Save Medical Cell Sciences & Technology Co., Ltd. ("SSMC"), a Taiwan-based dendritic cell immunotherapy platform. The LoI, executed on January 20, 2026,

Yahoo · Jan 13, 2026

YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations.

By Brad Sorensen, CFA NASDAQ:YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and regenerative ophthalmology under a single commercial and development strategy. The company’s mission centers on early cancer detection using blood-based diagnostic tests, the development of exosome-based therapeutics and tools for ophthalmic conditions,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By